TRP channels: New potential therapeutic approaches in CNS neuropathies

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 2, 2013, Pages 274-293

  Morelli, Maria Beatrice ^a   Amantini, Consuelo ^a   Liberati, Sonia ^b   Santoni, Matteo ^c   Nabissi, Massimo ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Alzheimer disease; Amyotrophic lateral sclerosis; Charcot Marie Tooth disease; Epilepsy; Neurological disorders; Parkinson disease; TRP channel

Indexed keywords

ALLYL ISOTHIOCYANATE; CAPSAZEPINE; CARVACROL; CITRAL; CLOTRIMAZOLE; CURCUMIN; ECONAZOLE; FLUFENAMIC ACID; MICONAZOLE; NAFAMSTAT MESILATE; NERVE GROWTH FACTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 3; TRANSIENT RECEPTOR POTENTIAL CHANNEL 4; TRANSIENT RECEPTOR POTENTIAL CHANNEL 5; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRANSIENT RECEPTOR POTENTIAL CHANNEL M; TRANSIENT RECEPTOR POTENTIAL CHANNEL M1; TRANSIENT RECEPTOR POTENTIAL CHANNEL M2; TRANSIENT RECEPTOR POTENTIAL CHANNEL M3; TRANSIENT RECEPTOR POTENTIAL CHANNEL M4; TRANSIENT RECEPTOR POTENTIAL CHANNEL M5; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 4;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN DAMAGE; DISEASE SEVERITY; ELECTROPHYSIOLOGY; EPILEPSY; EPILEPTOGENESIS; EXCITOTOXICITY; GENE EXPRESSION; HEREDITARY MOTOR SENSORY NEUROPATHY; HOMEOSTASIS; HUMAN; INCIDENCE; MISSENSE MUTATION; NEUROPATHY; NONHUMAN; PARKINSON DISEASE; PHOTOSENSITIVITY; POINT MUTATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; TRANSIENT RECEPTOR POTENTIAL CHANNELS;

EID: 84876705986     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113129990056     Document Type: Review

References (233)

1. Montell, C. The TRP superfamily of cation channels. Sci STKE., 2005, 272: re3.
2. Moran, M.M.; McAlexander, M.A.; Bíró, T.; Szallasi, A. Transient receptor potential channels as therapeutic targets. Nat. Rev. Drug Discov., 2011, 10(8), 601-620.
3. Patel, S.; Docampo, R. In with the TRP channels: intracellular functions for TRPM1 and TRPM2. Sci. Signal., 2009, 2(95), pe69.
4. Bandell, M.; Macpherson, L.J.; Patapoutian, A. From chills to chilis: mechanisms for thermosensation and chemesthesis via thermoTRPs. Curr. Opin. Neurobiol., 2007, 17(4), 490-497.
5. Santoni, G.; Farfariello, V.; Amantini, C. TRPV channels in tumor growth and progression. Adv. Exp. Med. Biol., 2011, 704, 947-967.
6. Amantini C, Mosca M, Nabissi M, Lucciarini R, Caprodossi S, Arcella A, Giangaspero F, Santoni G. Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J. Neurochem., 2007, 102(3), 977-990.
7. Nabissi, M.; Morelli, M.B.; Santoni, M.; Santoni, G. Triggering of the TRPV2 channel by Cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis, 2012, doi: 10.1093/carcin/bgs328.
8. Nabissi, M.; Morelli, M.B.; Amantini, C.; Farfariello, V.; Ricci-Vitiani, L.; Caprodossi, S.; Arcella, A.; Santoni, M.; Giangaspero, F.; De Maria, R.; Santoni, G. TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. Carcinogenesis, 2010, 31(5), 794-803.
9. Morelli, M.B.; Nabissi, M.; Amantini, C.; Farfariello, V.; Ricci-Vitiani, L.; di Martino, S.; Pallini, R.; Larocca, M.L.; Caprodossi, S.; Santoni, M.; De Maria, R.; Santoni, G. The Transient Receptor Potential Vanilloid-2 (TRPV2) cation channel impairs glioblastoma stem-like cell proliferation and promotes differentiation. Int. J. Cancer, 2012, 131(7), E1067-E1077.
10. Birder, L.A. TRPs in bladder diseases. Biochim. Biophys. Acta, 2007, 1772(8), 879-884.
11. Caprodossi, S.; Lucciarini, R., Amantini, C., Nabissi, M.; Canesin, G.; Ballarini, P.; Di Spilimbergo, A.; Cardarelli, M.A.; Servi, L.; Mammana, G.; Santoni, G. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage. Eur. Urol., 2008, 54(3), 612-620.
12. Jaggi, A.S.; Singh, N. Therapeutic targets for the management of peripheral nerve injury-induced neuropathic pain. CNS Neurol. Disord. Drug Targets, 2011, 10(5), 589-609.
13. Minke, B.; Cook, B. TRP channel proteins and signal transduction. Physiol. Rev., 2002, 82(2), 429-472.
14. Yuan, J.P.; Lee, K.P.; Hong, J.H.; Muallem, S. The closing and opening of TRPC channels by Homer1 and STIM1. Acta Physiol., 2012, 204(2), 238-247.
15. Brazer, S.C.; Singh, B.B.; Liu, X.; Swaim, W.; Ambudkar, I.S. Caveolin-1 contributes to assembly of store-operated Ca2+ influx channels by regulating plasma membrane localization of TRPC1. J. Biol. Chem., 2003, 278(29), 27208-27215.
16. Yuan, J.P.; Kiselyov, K.; Shin, D.M.; Chen, J.; Shcheynikov, N.; Kang, S.H.; Dehoff, M.H.; Schwarz, M.K.; Seeburg, P.H.; Muallem, S.; Worley, P.F. Homer binds TRPC family channels and is required for gating of TRPC1 by IP3 receptors. Cell, 2003, 114(6), 777-789.
17. Lockwich, T.; Pant, J.; Makusky, A.; Jankowska-Stephens, E.; Kowalak, J.A.; Markey, S.P.; Ambudkar, I.S. Analysis of TRPC3-interacting proteins by tandem mass spectrometry. J. Proteome Res., 2008, 7(3), 979-989.
18. Tang, Y.; Tang, J.; Chen, Z.; Trost, C.; Flockerzi, V.; Li, M.; Ramesh, V.; Zhu, M.X. Association of mammalian trp4 and phospholipase C isozymes with a PDZ domain-containing protein, NHERF. J. Biol. Chem. 2000, 275(48), 37559-37564.
19. Riccio, A.; Medhurst, A.D.; Mattei, C.; Kelsell, R.E.; Calver, A.R.; Randall, A.D.; Benham, C.D.; Pangalos, M.N. mRNA distribution analysis of human TRPC family in CNS and peripheral tissues. Brain Res. Mol. Brain Res., 2002, 109(1-2), 95-104.
20. Benham, C.D.; Davis, J.B.; Randall, A.D. Vanilloid and TRP channels: a family of lipid-gated cation channels. Neuropharmacology, 2002, 42(7), 873-888.
21. Gunthorpe, M.J.; Benham, C.D.; Randall, A.; Davis, J.B. The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol. Sci., 2002, 23(4), 183-191.
22. Ramsey, I.S.; Delling, M.; Clapham, D.E. An introduction to TRP channels. Annu. Rev. Physiol., 2006, 68, 619-647.
23. Jung, J.; Lee, S.Y.; Hwang, S.W.; Cho, H.; Shin, J.; Kang, Y.S.; Kim, S.; Oh, U. Agonist recognition sites in the cytosolic tails of vanilloid receptor 1. J. Biol. Chem., 2002, 277(46), 44448-44454.
24. Chang, Q.; Gyftogianni, E.; van de Graaf, S.F.; Hoefs, S.; Weidema, F.A.; Bindels, R.J.; Hoenderop, J.G.; Molecular determinants in TRPV5 channel assembly. J. Biol. Chem., 2004, 279(52), 54304-54311.
25. Erler, I.; Hirnet, D.; Wissenbach, U.; Flockerzi, V.; Niemeyer, B.A. Ca2+-selective transient receptor potential V channel architecture and function require a specific ankyrin repeat. J. Biol. Chem., 2004, 279(33), 34456-34463.
26. Hellwig, N.; Albrecht, N.; Harteneck, C.; Schultz, G.; Schaefer, M. Homo-and heteromeric assembly of TRPV channel subunits. J. Cell Sci., 2005, 118(5), 917-928.
27. Arniges, M.; Fernandez-Fernandez, J.M; Albrecht, N.; Schaefer, M.; Valverde, M.A. Human TRPV4 channel splice variants revealed a key role of ankyrin domains in multimerization and trafficking. J. Biol. Chem., 2006, 281(3), 1580-1586.
28. Morenilla-Palao, C.; Planells-Cases, R.; García-Sanz, N.; Ferrer-Montiel, A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J. Biol. Chem., 2004, 279(24), 25665-25672.
29. Kauer, J.A.; Gibson, H.E. Hot flash: TRPV channels in the brain. Trends Neurosci., 2009, 32(4), 215-224.
30. Audo, I.; Robson, A.G.; Holder, G.E.; Moore, A.T. The negative ERG: clinical phenotypes and disease mechanisms of inner retinal dysfunction. Surv. Ophthalmol., 2008, 53(1), 16-40
31. Jiang, L.H. Subunit interaction in channel assembly and functional regulation of transient receptor potential melastatin (TRPM) channels. Biochem. Soc. Trans., 2007, 35(Pt 1), 86-88.
32. Kühn, F.J.; Lückhoff, A. Sites of the NUDT9-H domain critical for ADP-ribose activation of the cation channel TRPM2. J. Biol. Chem., 2004, 279(45), 46431-46437.
33. Earley, S. Vanilloid and melastatin transient receptor potential channels in vascular smooth muscle. Microcirculation, 2010, 17(4), 237-249.
34. Fonfria, E.; Murdock, P.R.; Cusdin, F.S.; Benham, C.D.; Kelsell, R.E.; McNulty, S. Tissue distribution profiles of the human TRPM cation channel family. J. Recept. Signal Transduct. Res., 2006, 26(3), 159-178.
35. Lee, N.; Chen, J.; Sun, L.; Wu, S.; Gray, K.R.; Rich, A.; Huang, M.; Lin, J.H.; Feder, J.N., Janovitz, E.B.; Levesque, P.C.; Blanar, M.A. Expression and characterization of human transient receptor potential melastatin 3 (hTRPM3). J. Biol. Chem., 2003, 278(23), 20890-20897.
36. Clapham, D.E. Transient Receptor Potential (TRP) Channels. In: Squire LR (ed.) Encyclopedia of Neuroscience, vol. 9, 1109-1133. Oxford: Academic Press; 2009.
37. Delmas, P.; Padilla, F.; Osorio, N.; Coste, B.; Raoux, M.; Crest, M. Polycystins, calcium signaling, and human diseases. Biochem. Biophys. Res. Commun., 2004, 322(4), 1374-1383.
38. Shimizu, T.; Janssens, A.; Voets, T.; Nilius, B. Regulation of the murine TRPP3 channel by voltage, pH, and changes in cell volume. Pflugers Arch., 2009, 457(4), 795-807.
39. Nilius, B.; Owsianik, G. The transient receptor potential family of ion channels. Genome Biol., 2011, 12(3), 218-228.
40. Ohnuki, K.; Haramizu, S.; Oki, K.; Watanabe, T.; Yazawa, S.; Fushiki T. Administration of capsiate, a non-pungent capsaicin analog, promotes energy metabolism and suppresses body fat accumulation in mice. Biosci. Biotechnol. Biochem., 2001, 65(12), 2735-2740.
41. Hwang, S.W.; Cho, H.; Kwak, J.; Lee, S.Y.; Kang, C.J.; Jung, J.; Cho, S.; Min, K.H.; Suh, Y.G.; Kim, D.; Oh, U. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc. Natl. Acad. Sci. USA, 2000, 97(11), 6155-6160.
42. Huang, S.M.; Bisogno, T.; Trevisani, M.; Al-Hayani, A.; De Petrocellis, L.; Fezza, F.; Tognetto, M.; Petros, T.J.; Krey, J.F.; Chu, C.J.; Miller, J.D.; Davies, S.N.; Geppetti, P.; Walzer, J.M.; Di Marzo, V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. USA, 2002, 99(12), 8400-8405.
43. Brand, L.; Berman, E.; Schwen, R.; Loomans, M.; Janusz, J.; Bohne, R.; Maddin, C.; Gardner, J., Lahann, T.; Farmer, R. et al. NE-19550: a novel, orally active anti-inflammatory analgesic. Drugs Exp. Clin. Res., 1987, 13(5), 259-265.
44. Melck, D.; Bisogno, T.; De Petrocellis, L.; Chuang, H.; Julius, D.; Bifulco, M.; Di Marzo, V. Unsaturated long-chain N-acyl-vanillylamides (N-AVAMs), vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem. Biophys. Res. Commun., 1999, 262(1), 275-284.
45. Liu, L.; Simon, S.A. Similarities and differences in the currents activated by capsaicin, piperine, and zingerone in rat trigeminal ganglion cells. J. Neurophysiol., 1996, 76(3), 1858-1869.
46. Salazar, H.; Llorente, I.; Jara-Oseguera, A.; García-Villegas, R.; Munari, M.; Gordon, S.E.; Islas, L.D.; Rosenbaum, T. A single Nterminal cysteine in TRPV1 determines activation by pungent compounds from onion and garlic. Nat. Neurosci., 2008, 11(3), 255-261.
47. Siemens, J.; Zhou, S.; Piskorowski, R.; Nikai, T.; Lumpkin, E.A.; Basbaum, A.I.; King, D.; Julius, D. Spider toxins activate the capsaicin receptor to produce inflammatory pain. Nature, 2006, 444(7116), 208-212.
48. Appendino, G.; De Petrocellis, L.; Trevisani, M.; Minassi, A.; Daddario, N.; Morello, A.S.; Mazzieri, D.; Ligresti, A.; Campi, B.; Fontana, G.; Pinna, C.; Geppetti, P.; Di Marzo, V. Development of the first ultra-potent "capsaicinoid" agonist at transient receptor potential vanilloid type 1 (TRPV1) channels and its therapeutic potential. J. Pharmacol. Exp. Ther., 2005, 312(2), 561-570.
49. Güler, A.D.; Lee, H.; Iida, T.; Shimizu, I.; Tominaga, M.; Caterina, M. Heat-evoked activation of the ion channel, TRPV4. J. Neurosci., 2002, 22(15), 6408-6414.
50. Watanabe, H.; Vriens, J.; Prenen, J.; Droogmans, G.; Voets, T.; Nilius, B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature, 2003, 424(6947), 434-438.
51. Watanabe, H.; Davis, J.B.; Smart, D.; Jerman, J.C.; Smith, G.D.; Hayes, P.; Vriens, J.; Cairns, W.; Wissenbach, U.; Prenen, J.; Flockerzi, V.; Droogmans, G.; Benham, C.D.; Nilius, B. Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives. J. Biol. Chem., 2002, 277(16), 13569-13577.
52. Vincent, F.; Duncton, M.A. TRPV4 agonists and antagonists. Curr. Top. Med. Chem., 2011, 11(17), 2216-2226.
53. Hara, Y.; Wakamori, M.; Ishii, M.; Maeno, E.; Nishida, M., Yoshida T, Yamada H, Shimizu S, Mori E, Kudoh J, Shimizu N, Kurose H, Okada Y, Imoto K, Mori Y. LRPC2 Ca2+-permeable channel activated by changes in redox status confers susceptibility to cell death. Mol. Cell, 2002, 9(1), 163-173.
54. Perraud, A.L.; Fleig, A.; Dunn, C.A.; Bagley, L.A.; Launay, P.; Schmitz, C.; Stokes, A.J.; Zhu, Q.; Bessman, M.J.; Penner, R.; Kinet, J.P.; Scharenberg, A.M. ADP-ribose gating of the calciumpermeable LTRPC2 channel revealed by Nudix motif homology. Nature, 2001, 411(6837), 595-599.
55. Beck, A.; Kolisek, M.; Bagley, L.A.; Fleig, A.; Penner, R. Nicotinic acid adenine dinucleotide phosphate and cyclic ADPribose regulate TRPM2 channels in T lymphocytes. FASEB J., 2006, 20(7), 962-964.
56. Chen X, Numata T, Li M, Mori Y, Orser BA, Jackson MF, Xiong ZG, MacDonald JF. The modulation of TRPM7 currents by nafamostat mesilate depends directly upon extracellular concentrations of divalent cations. Mol. Brain, 2010, 3, 38-50.
57. Clark, K.; Langeslag, M.; van Leeuwen, B.; Ran, L.; Ryazanov, A.G.; Figdor, C.G.; Moolenaar, W.H.; Jalink, K.; van Leeuwen, F.N. TRPM7, a novel regulator of actomyosin contractility and cell adhesion. EMBO J., 2006, 25(5), 290-301
58. Runnels, L.W.; Yue, L.; Clapham, D.E. The TRPM7 channel is inactivated by PIP(2) hydrolysis. Nat. Cell Biol., 2002, 4(5), 329-336.
59. Kerschbaum, H.H.; Kozak, J.A.; Cahalan, M.D. Polyvalent cations as permeant probes of MIC and TRPM7 pores. Biophys. J., 2003, 84(4), 2293-2305.
60. Jiang, J.; Li, M.; Yue, L. Potentiation of TRPM7 inward currents by protons. J. Gen. Physiol., 2005, 126(2), 137-150.
61. McKemy, D.D.; Neuhausser, W.M.; Julius, D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature, 2002, 416(6876), 52-58.
62. Behrendt, H.J.; Germann, T.; Gillen, C.; Hatt, H.; Jostock, R. Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br. J. Pharmacol., 2004, 141(4), 737-745.
63. Walker, R.L.; Koh, S.D.; Sergeant, G.P.; Sanders, K.M.; Horowitz, B. TRPC4 currents have properties similar to the pacemaker current in interstitial cells of Cajal. Am. J. Physiol. Cell Physiol., 2002, 283(6), C1637-C1645.
64. Zimmermann, K.; Lennerz, J.K.; Hein, A.; Link, A.S.; Kaczmarek, J.S.; Delling, M.; Uysal, S.; Pfeifer, J.D.; Riccio, A.; Clapham, D.E. Transient receptor potential cation channel, subfamily C, member 5 (TRPC5) is a cold-transducer in the peripheral nervous system. PNAS, 2011, 108(44), 18114-18119.
65. Majeed, Y.; Bahnasi, Y.; Seymour, V.A.; Wilson, L.A.; Milligan, C.J.; Agarwal, A.K.; Sukumar, P.; Naylor, J.; Beech, D.J. Rapid and Contrasting Effects of Rosiglitazone on Transient Receptor Potential TRPM3 and TRPC5 Channels. Mol. Pharmacol., 2011, 79(6), 1023-1030.
66. Bandell, M.; Story, G.M.; Hwang, S.W.; Viswanath, V.; Eid, S.R.; Petrus, M.J.; Earley, T.J.; Patapoutian, A. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron, 2004, 41(6), 849-857.
67. Talavera, K.; Gees, M.; Karashima, Y.; Meseguer, V.M.; Vanoirbeek, J.A.; Damann, N.; Everaerts, W.; Benoit, M.; Janssens, A.; Vennekens, R.; Viana, F.; Nemery, B.; Nilius, B.; Voets, T. Nicotine activates the chemosensory cation channel TRPA1. Nat. Neurosci., 2009, 12(10), 1293-1299.
68. Nassini, R.; Materazzi, S.; Vriens, J.; Prenen, J.; Benemei, S.; De Siena, G.; la Marca, G.; Andrè, E.; Preti, D.; Avonto, C.; Sadofsky, L.; Di Marzo, V.; De Petrocellis, L.; Dussor, G.; Porreca, F.; Taglialatela-Scafati, O.; Appendino, G.; Nilius, B.; Geppetti, P. The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system. Brain, 2012, 135(Pt 2), 376-390.
69. Zhong, J.; Pollastro, F.; Prenen, J.; Zhu, Z.; Appendino, G.; Nilius, B. Ligustilide: a novel TRPA1 modulator. Pflugers Arch., 2011, 462(6), 841-849.
70. Ryckmans, T.; Aubdool, A.A.; Bodkin, J.V.; Cox, P.; Brain, S.D.; Dupont, T.; Fairman, E.; Hashizume, Y.; Ishii, N.; Kato, T.; Kitching, L.; Newman, J.; Omoto, K.; Rawson, D.; Strover, J. Design and pharmacological evaluation of PF-4840154, a nonelectrophilic reference agonist of the TrpA1 channel. Bioorg. Med. Chem. Lett., 2011, 21(16), 4857-4859.
71. Gu, Q.; Lin, R.L. Heavy metals zinc, cadmium, and copper stimulate pulmonary sensory neurons via direct activation of TRPA1. J. Appl. Physiol., 2010, 108(4), 891-897.
72. Taylor-Clark, T.E.; McAlexander, M.A.; Nassenstein, C.; Sheardown, S.A.; Wilson, S.; Thornton, J.; Carr, M.J., Undem, B.J. Relative contributions of TRPA1 and TRPV1 channels in the activation of vagal bronchopulmonary C-fibres by the endogenous autacoid 4-oxononenal. J. Physiol., 2008, 586(14), 3447-3459.
73. Takahashi, N.; Mizuno, Y.; Kozai, D.; Yamamoto, S.; Kiyonaka, S.; Shibata, T.; Uchida, K.; Mori, Y. Molecular characterization of TRPA1 channel activation by cysteine-reactive inflammatory mediators. Channels (Austin), 2008, 2(4), 287-298.
74. Leamy, A.W.; Shukla, P.; McAlexander, M.A.; Carr, M.J.; Ghatta, S. Curcumin [(E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] activates and desensitizes the nociceptor ion channel TRPA1. Neurosci. Lett., 2011, 503(3), 157-162.
75. Wahl, P.; Foged, C.; Tullin, S.; Thomsen, C. Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist. Mol. Pharmacol., 2001, 59(1), 9-15.
76. Valenzano, K.J.; Grant, E.R.; Wu, G.; Hachicha, M.; Schmid, L.; Tafesse, L.; Sun, Q.; Rotshteyn, Y.; Francis, J.; Limberis, J.; Malik, S.; Whittemore, E.R.; Hodges, D. N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties. J. Pharmacol. Exp. Ther., 2003, 306(1), 377-386.
77. Vincent, F.; Acevedo, A.; Nguyen, M.T.; Dourado, M.; DeFalco, J.; Gustafson, A.; Spiro, P.; Emerling, D.E.; Kelly, M.G.; Duncton, M.A. Identification and characterization of novel TRPV4 modulators. Biochem. Biophys. Res. Commun., 2009, 389(3), 490-494.
78. Martin, E.; Dahan, D.; Cardouat, G.; Gillibert-Duplantier, J.; Marthan, R.; Savineau, J.P.; Ducret, T. Involvement of TRPV1 and TRPV4 channels in migration of rat pulmonary arterial smooth muscle cells. Pflugers Arch., 2012, 464(3), 261-272.
79. Vincent, F.; Duncton M.A. TRPV4 agonists and antagonists. Curr. Top. Med. Chem., 2011, 11(17), 2216-2226.
80. Knowlton, W.M.; Daniels, R.L.; Palkar, R.; McCoy, D.D.; McKemy, D.D. Pharmacological blockade of TRPM8 ion channels alters cold and cold pain responses in mice. PLoS ONE, 2011, 6(9), e25894.
81. Miller, M.; Shi, J.; Zhu, Y.; Kustov, M.; Tian, J.; Stevens, A.; Wu, M.; Xu, J.; Long, S.; Yang, P., Zholos, A.V.; Salovich, J.M.; Weaver, C.D.; Hopkins, C.R.; Lindsley, C.W.; McManus, O.; Li, M.; Zhu, M.X. Identification of ML204, a Novel Potent Antagonist That Selectively Modulates Native TRPC4/C5 Ion Channels. J. Biol. Chem., 2011, 286(38), 33436-33446.
82. Li J.X.; Zhang, Y. Emerging drug targets for pain treatment. Eur. J. Pharmacol., 2012, 681(1-3), 1-5.
83. McGaraughty, S.; Chu, K.; Perner, R.; DiDomenico, S.; Kort, M.; Kym, P. TRPA1 modulation of spontaneous and mechanically evoked firing of spinal neurons in uninjured, osteoarthritic, and inflamed rats. Mol. Pain, 2010, 6, 14.
84. Gijsen, H.J.; Berthelot, D.; De Cleyn, M.A.; Geuens, I.; Brone, B.; Mercken, M. Tricyclic 3,4-dihydropyrimidin-2-thione derivatives as potent TRPA1 antagonists. Bioorg. Med. Chem. Lett., 2012, 22(2), 797-800.
85. Li, H.B. Antistress effect of TRPV1 channel on synaptic plasticity and spatial memory. Biol. Psychiat., 2008, 64, 286-292.
86. Gibson, H.E.; Page, R.S.; Van Hook, M.J.; Kauer, J.A. TRPV1 channels mediate longterm depression at synapses on hippocampal interneurons. Neuron, 2008, 57, 746-759.
87. Lee, T.H.; Lee, J.G.; Yon, J.M.; Oh, K.W.; Baek, I.J.; Nahm, S.S.; Lee, B.J.; Yun, Y.W.; Nam, S.Y. Capsaicin prevents kainic acidinduced epileptogenesis in mice. Neurochem. Int., 2011, 58(6), 634-640.
88. Micale, V.; Cristino, L.; Tamburella, A.; Petrosino, S.; Leggio, G.M.; Di Marzo, V.; Drago, F. Enhanced cognitive performance of dopamine D3 receptor knock-out mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems. Pharmacol. Res., 2010, 61(6), 531-536.
89. Donarium, E.A.; Halperin, R.F.; Stephan, D.A.; Narayanan, V. Cognitive dysfunction in NFI knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex. BMC Neurosci., 2006, 7, 22-32.
90. Chen, D.H.; Sul, Y.; Weiss, M.; Hillel, A.; Lipe, H.; Wolff, J.; Matsushita, M.; Raskind, W.; Bird, T. CMT2C with vocal cord paresis associated with short stature and mutations in the TRPV4 gene. Neurology, 2010, 75(22), 1968-1975.
91. Landoure, G.; Zdebik, A.A.; Martinez, T.L.; Burnett, B.G.; Stanescu, H.C.; Inada, H.; Shi, Y.; Taye, A.A.; Kong, L.; Munns, C.H.; Choo, S.S.; Phelps, C.B.; Paudel, R.; Houlden, H.; Ludlow, C.L.; Caterina, M.J.; Gaudet, R.; Kleta, R.; Fischbeck, K.H.; Sumner, C.J. Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2C. Nat. Genet., 2010, 42(2), 170-174.
92. Auer-Grumbach, M.; Olschewski, A.; Papic, L.; Kremer, H.; McEntagart, M.E.; Uhrig, S.; Fischer, C.; Fröhlich, E.; Bálint, Z.; Tang, B.; Strohmaier, H.; Lochmüller, H.; Schlotter-Weigel, B.; Senderek, J.; Krebs, A.; Dick, K.J.; Petty, R.; Longman, C.; Anderson, N.E.; Padberg, G.W.; Schelhaas, H.J.; van Ravenswaaij-Arts, C.M.A.; Pieber, T.R.; Crosby, A.H.; Guelly, C. Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat. Genet., 2010, 42(2), 160-164.
93. Klein, C.J.; Shi, Y.; Fecto, F.; Donaghy, M.; Nicholson, G.; McEntagart, M.E.; Crosby, A.H.; Wu, Y.; Lou, H.; McEvoy, K.M.; Siddique, T.; Deng, H.X.; Dyck, P.J. TRPV4 mutations and cytotoxic hypercalcemia in axonal Charcot-Marie-Tooth neuropathies. Neurology, 2011, 76(10), 887-894.
94. Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O'Regan, J.P.; Deng, H.X. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 1993, 362(6415), 59-62.
95. Hermosura, M.C.; Cui, A.M.; Go, R.C.; Davenport, B.; Shetler, C.M.; Heizer, J.W.; Schmitz, C.; r Mocz, G.; Garruto, R.M.; Perraud, A.L. Altered functional properties of a TRPM2 variant in Guamanian ALS and PD. Proc. Natl. Acad. Sci. USA, 2008, 105(46), 18029-18034.
96. Kaneko, S.; Kawakami, S.; Hara, Y.; Wakamori, M.; Itoh, E.; Minami, T.; Takada, Y.; Kume, T.; Katsuki, H.; Mori, Y.; Akaike, A. Critical role of TRPM2 in neuronal cell death by hydrogen peroxide. J. Pharmacol. Sci., 2006, 101(1), 66-76.
97. Fonfria, E.; Marshall, I.C.; Boyfield, I.; Skaper, S.D.; Hughes, J.P.; Owen, D.E.; Zhang, W.; Miller, B.A.; Benham, C.D.; McNulty, S. Amyloid beta-peptide(1-42) and hydrogen peroxide-induced toxicity are mediated by TRPM2 in rat primary striatal cultures. Neurochemistry, 2005, 95(3), 715-723.
98. Aarts, M.M.; Tymianski, M. TRPMs and neuronal cell death. Pflugers Arch., 2005, 451(1), 243-249.
99. Heinemann, U.; Lux, H.D.; Gutnick, M.J. Extracellular free calcium and potassium during paroxysmal activity in the cerebral cortex of the cat. Exp. Brain Res., 1977, 27, 237-243.
100. Hentati, A.; Ouahchi, K.; Pericak-Vance, M.A.; Nijhawan, D.; Ahmad, A.; Yang, Y.; Rimmler, J.; Hung, W.; Schlotter, B.; Ahmed, A.; Ben Hamida, M.; Hentati, F.; Siddique, T. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Neurogenetics, 1998, 2(1), 55-60.
101. Hermosura, M.C.; Nayakanti, H.; Dorovkov, M.V.; Calderon, F.R.; Ryazanov, A.G.; Haymer, D.S.; Garruto, R.M. A TRPM7 variant shows altered sensitivity to magnesium that may contribute to the pathogenesis of two Guamanian neurodegenerative disorders. Proc. Natl. Acad. Sci. USA, 2005, 102(32), 11510-11515.
102. Lendman, N.; Jeong, S.Y.; Shin, S.Y.; Voronov, S.V.; Serban, G.; Kang, M.S.; Park, M.K.; Di Paolo, G.; Chung, S.; Kim, T. Presenilin mutations linked to familial Alzheimer'sdisease cause an imbalance in phosphatidylinositol 4,5-biphosphate metabolism. Proc. Natl. Acad. Sci. USA, 2006, 103(51), 19524-19529.
103. Inoue, K.; Branigan, D.; Xiong, Z.G. Zinc-induced neurotoxicity mediated by transient receptor potential melastatin 7 channels. J. Biol. Chem., 2010, 285(10), 7430-7439.
104. Tozzi, A.; Bengtson, C.P.; Longone, P.; Carignani, C.; Fusco, F.R.; Bernardi, G.; Mercuri, N.B. Involvement of transient receptor potential-like channels in responses to mGluR-I activation in midbrain dopamine neurons. Eur. J. Neurosci., 2003, 18(8), 2133-2145.
105. Cucchiaroni, M.L.; Viscomi, M.T.; Bernardi, G.; Molinari, M.; Guatteo, E.; Mercuri, N.B. Metabotropic Glutamate Receptor 1 Mediates the Electrophysiological and Toxic Actions of the Cycad Derivative b-N-Methylamino-L-Alanine on Substantia Nigra Pars Compacta DAergic Neurons. J. Neurosci., 2010, 30(15), 5176-5188.
106. Bollimuntha, S.; Singh, B.B.; Shavali, S.; Sharma, S.K.; Ebadi, M. TRPC1-mediated inhibition of 1-methyl-4-phenylpyridinium ion neurotoxicity in human SH-SY5Y neuroblastoma cells. J. Biol. Chem., 2005, 280(3), 2132-2140.
107. Selvaraj, S.; Sun, Y.; Watt, J.A.; Wang, S.; Lei, S.; Birnbaumer, L.; Singh, B.B. Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. J. Clin. Invest., 2012, 122(4), 1354-1367. doi: 10.1172/JCI61332.
108. Yamamoto, S.; Wajima, T.; Hara, Y.; Nishida, M.; Mori, Y. Transient receptor potential channels in Alzheimer's disease. Biochim. Biophys. Acta, 2007, 1772(8), 958-967.
109. Wang, M.; Bianchi, R.; Chuang, S.C.; Zhao, W.; Wong, R.K. Group I metabotropic glutamate receptor-dependent TRPC channel trafficking in hippocampal neurons. J. Neurochem., 2007, 101(2), 411-421.
110. von Spiczak, S.; Muhle, H.; Helbig, I.; de Kovel, C.G.; Hampe, J.; Gaus, V.; Koeleman, B.P.; Lindhout, D.; Schreiber, S.; Sander, T.; Stephani, U. Association study of TRPC4 as a candidate gene for generalized epilepsy with photosensitivity. Neuromol. Med., 2010, 12(3), 292-299.
111. Tai, C.; Hines, D.J.; Choi, H.B.; Macvicar, B.A. Plasma membrane insertion of TRPC5 channels contributes to the cholinergic plateau potential in hippocampal CA1 pyramidal neurons. Hippocampus, 2010, 21(9), 958-967.
112. Lessard, C.B.; Lussier, M.P.; Cayouette, S.; Bourque, G.; Boulay, G. The overexpression of presenilin2 and Alzheimer's-diseaselinked presenilin2 variants influences TRPC6-enhanced Ca2+ entry into HEK293 cells. Cell Signal., 2005, 17(4), 437-445.
113. Sander, J.W. The epidemiology of epilepsy revisited. Curr. Opin. Neurol., 2003, 16(2), 165-170.
114. Poduri, A.; Lowenstein, D. Epilepsy genetics past, present, and future. Curr. Opin. Genet. Dev., 2011, 21(3), 325-332.
115. Reboreda, A.; Jiménez-Díaz, L.; Navarro-López, J.D. TRP channels and neural persistent activity. Adv. Exp. Med. Biol., 2011, 704, 595-613.
116. Rajakulendran, S.; Kaski, D.; Hanna, M.G. Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS. Nat. Rev. Neurol., 2012, 8(2), 86-96.
117. Pape, H.C.; Munsch, T.; Budde, T. Novel vistas of calciummediated signalling in the thalamus. Pflugers Arch., 2004, 448(2), 131-138.
118. Venkatachalam, K.; Montell, C. TRP channels. Annu. Rev. Biochem., 2007, 76, 387-417.
119. Strubing, C.; Krapivinsky, G.; Krapivinsky, L.; Clapham, D.E. TRPC1 and TRPC5 form a novel cation channel in mammalian brain. Neuron, 2001, 29, 645-655.
120. Clapham, D.E.; Runnels, L.W.; Strubing, C. The TRP ion channel family. Nat. Rev. Neurosci., 2001, 2, 387-396.
121. Strubing, C.; Krapivinsky, G.; Krapivinsky, L.; Clapham, D.E. Formation of novel TRPC channels by complex subunit interactions in embryonic brain. J. Biol. Chem., 2003, 278, 39014-39019.
122. McGaughy, J.; Koene, R.A.; Eichenbaum, H.; Hasselmo, M.E. Cholinergic deafferentation of the entorhinal cortex in rats impairs encoding of novel but not familiar stimuli in a delayed nonmatchto-sample task. J. Neurosci., 2005, 25(44), 10273-10281.
123. Zhao, W.; Bianchi, R.; Wang, M.; Wong, R.K.S. Extracellular signal-regulated kinase 1/2 is required for the induction of group I metabotropic glutamate receptor-mediated epileptiform discharges. J. Neurosci., 2004, 24, 76-84.
124. 2+ wave-dependent activation of SK and TRPC channels. J. Physiol., 2011, 589(13), 3211-3229.
125. Covanis, A. Photosensitivity in idiopathic generalized epilepsies. Epilepsia, 2005, 46(9), 67-72.
126. Stephani, U.; Tauer, U.; Koeleman, B.; Pinto, D.; Neubauer, B.A.; Lindhout, D. Genetics of photosensitivity (photoparoxysmal response), A review. Epilepsia, 2004, 45(1), 19-23.
127. Olney, J.W. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science, 1969, 164, 719-721.
128. Aarts, M.; Iihara, K.; Wei, W.L.; Xiong, Z.G.; Arundine, M.; Cerwinski, W.; MacDonald, J.F.; Tymianski, M. A key role for TRPM7 channels in anoxic neuronal death. Cell, 2003, 115, 863-877.
129. Peier, A.M., Moqrich, A.; Hergarden, A.C.; Reeve, A.J.; Andersson, D.A.; Story, G.M.; Earley, T.J.; Dragoni, I.; McIntyre, P.; Bevan, S.; Patapoutian, A. A TRP channel that senses cold stimuli and menthol. Cell, 2002, 108, 705-715.
130. Zuker, C.S. Neurobiology: a cool ion channel. Nature, 2002, 416, 27-28.
131. Tsuzuki, K.; Xing, H.; Ling, J.; Gu, J.G. Menthol-induced Ca2+ release from presynaptic Ca2+ stores potentiates sensory synaptic transmission. J. Neurosci., 2004, 24(3), 762-771.
132. Houser, C.R.; Esclapez, M. Downregulation of the alpha5 subunit of the GABAA receptor in the pilocarpine model of temporal lobe epilepsy. Hippocampus, 2003, 13, 633-645.
133. Zhang, X.B.; Jiang, P.; Gong, N.; Hu, X.L.; Fei, D.; Xiong, Z.Q.; Xu, L.; Xu, T.L. A-Type GABA Receptor as a Central Target of TRPM8 Agonist Menthol. PLoS One, 2008, 3(10), 1-11.
134. Julius, D.; Basbaum, A.I. Molecular mechanisms of nociception. Nature, 2001, 413, 203-10.
135. Caterina, M.J.; Julius, D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu. Rev. Neurosci., 2001, 24, 487-517.
136. Cristino, L.; de Petrocellis, L.; Pryce, G.; Baker, D.; Guglielmotti, V.; Di Marzo, V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience, 2006, 139(4), 1405-1415.
137. Liapi, A.; Wood, J.N. Extensive co-localization and heteromultimer formation of the vanilloid receptor-like protein TRPV2 and the capsaicin receptor TRPV1 in the adult rat cerebral cortex. Eur. J. Neurosci., 2005, 22(4), 825-834.
138. Mezey, E.; Tóth, Z.E.; Cortright, D.N.; Arzubi, M.K.; Krause, J.E.; Elde, R.; Guo, A.; Blumberg, P.M.; Szallasi, A. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl. Acad. Sci. USA, 2000, 97(7), 3655-3660.
139. Hill, M.N.; Patel, S.; Carrier, E.J.; Rademacher, D.J.; Ormerod, B.K.; Hillard, C.J.; Gorzalka, B.B. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychophamacology, 2005, 30, 508-515.
140. Bonnington, J.K.; McNaughton, P.A. Signalling pathways involved in the sensitisation of mouse nociceptive neurones by nerve growth factor. J. Physiol., 2003, 551, 433-446.
141. Zhang, X.; Huang, J.; McNaughton, P.A. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J., 2005, 24(24), 4211-4223.
142. Chevaleyre, V.; Takahashi, K.A.; Castillo, P.E. Endocannabinoidmediated synaptic plasticity in the CNS. Annu. Rev. Neurosci., 2006, 29, 37-76.
143. Steffens, M.; Huppertz, H.J.; Zentner, J.; Chauzit, E.; Feuerstein, T.J. Fatty acid amidohydrolase in human neocortex-activity in epileptic and non-epileptic brain tissue and inhibition by putative endocannabinoids. Neurosci. Lett., 2005, 385, 13-17.
144. Clement, A.B.; Hawkins, E.G.; Lichtman, A.H.; Cravatt, B.F. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J. Neurosci., 2003, 23(9), 3916-3923.
145. Hill, A.J.; Williams, C.M.; Whalley, B.J.; Stephens, G.J. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol. Ther., 2012, 133(1), 79-97.
146. Qin, N.; Neeper, M.P.; Liu, Y.; Hutchinson, T.L.; Lubin, M.L.; Flores, C.M. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J. Neurosci., 2008, 28(24), 6231-6238.
147. Jones, N.A.; Hill, A.J.; Smith, I.; Bevan, S.A.; Williams, C.M.; Whalley, B.J.; Stephens, G.J. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J. Pharmacol. Exp. Ther., 2010, 332(2), 569-577.
148. Müller M.; Pape, H.C.; Speckmann, E.J.; Gorji, A. Effect of eugenol on spreading depression and epileptiform discharges in rat neocortical and hippocampal tissues. Neuroscience, 2006, 140(2), 743-751.
149. Barisic, N.; Claeys, K.G.; Sirotković-Skerlev, M.; Lofgren, A.; Nelis, E.; De Jonghe, P.; Timmerman, V. Charcot-Marie-Tooth disease: a clinico-genetic confrontation. Ann. Hum. Genet., 2008, 72(3), 416-441.
150. Szigeti, K.; Lupski, J.R. Charcot-Marie-Tooth disease. Eur. J. Hum. Genet., 2009, 17(6), 703-710.
151. Scherer, S.S; Wrabetz, L. Molecular mechanisms of inherited demyelinating neuropathies. Glia, 2008, 56(14), 1578-1589.
152. Pareyson, D.; Scaioli, V.; Laurà, M. Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease. Neuromol. Med., 2006, 8(1-2), 3-22.
153. Krajewski, K.M.; Lewis, R.A.; Fuerst, D.R.; Turansky, C.; Hinderer, S.R.; Garbem, J.; Kamholz, J.; Shy, M.E. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain, 2000, 123(7), 1516-1527.
154. Lupski, J.R.; de Oca-Luna, R.M.; Slaugenhaupt, S.; Pentao, L.; Guzzetta, V., Trask, B.J.; Saucedo-Cardenas, O.; Barker, D.F.; Killian, J.M.; Garcia, C.A.; Chakravarti, A.; Patel, P.I. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell, 1991, 66(2), 219-232.
155. Raeymaekers, P.; Timmerman, V.; Nelis, E.; De Jonghe, P.; Hoogendijk, J.E.; Baas, F.; Barker, D.F.; Martin, J.J.; De Visser, M.; Bolhuis, P.A.; Van Broeckhoven, C. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul. Disord., 1991, 1(2), 93-97.
156. Khajavi, M.; Inoue, K.; Wiszniewski, W.; Ohyama, T.; Snipes, G.J.; Lupski, J.R. Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants. Am. J. Hum. Genet., 2005, 77(5), 841-850.
157. Khajavi, M.; Shiga, K.; Wiszniewski, W.; He, F.; Shaw, C.A.; Yan, J.; Wensel, T.G.; Snipes, G.J.; Lupski, J.R. Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inheritedneuropathy. Am. J. Hum. Genet., 2007, 81(3), 438-453.
158. Liedtke, W.; Choe, Y.; Marti-Renom, M.A.; Bell, A.M.; Denis, C.S.; Sali, A.; Hudspeth, A.J.; Friedman, J.M.; Heller, S. Vanilloid receptor-related osmotically activated channel [VR-OAC], a candidate vertebrate osmoreceptor. Cell, 2000, 103(3), 525-535.
159. Plant, T.D.; Strotmann, R. Trpv4. Handb. Exp. Pharmacol., 2007, (179), 189-205.
160. Everaerts, W.; Nilius, B.; Owsianik, G. The vallinoid transient receptor potential channel Trpv4: from structure to disease. Prog. Biophys. Mol. Biol., 2010, 103(1), 2-17.
161. Phelps, C.B.; Wang, R.R.; Choo, S.S.; Gaudet, R. Differential regulation of TRPV1, TRPV3, and TRPV4 sensitivity through a conserved binding site on the ankyrin repeat domain. J. Biol. Chem., 2009, 285(1), 731-740.
162. Mattson, M.P. Calcium and neurodegeneration. Aging Cell, 2007, 6(3), 337-350.
163. Nilius, B.; Watanabe, H.; Vriens, J. The TRPV4 channel: structurefunction relationship and promiscuous gating behaviour. Pflugers Arch., 2003, 446(3), 298-303.
164. Nilius, B.; Owsianik, G.; Voets, T.; Peters, J.A. Transient receptor potential cation channels in disease. Physiol. Rev., 2007, 87(1), 165-217.
165. Erler, I.; Al-Ansary, D.M; Wissenbach, U.; Wagner, T.F; Flockerzi, V.; Niemeyer, B.A. Trafficking and assembly of the cold-sensitive TRPM8 channel. J. Biol. Chem., 2006, 281(50), 38396-38404.
166. Deng, H.X.; Klein, C.J.; Yan, J.; Shi, Y.; Wu, Y.; Fecto, F.; Yau, Y.; Zhai, H.; Siddique, N.; Hedley-Whyte, E.T.; Delong, R.; Martina, M.; Dyck, P.J.; Siddique, T. Scapuloperoneal spinal muscular atrophy and CMT2C are allelic disorders caused by alterations in TRPV4. Nat. Genet., 2010, 42(2), 165-169.
167. Zimon, M.; Baets, J.; Auer-Grumbach, M.; Berciano, J.; Garcia, A.; Lopez-Laso, E.; Merlini, L.; Hilton-Jones, D.; McEntagart, M.; Crosby, A.H.; Barisic, N.; Boltshauser, E.; Shaw, C.E.; Landoure, G.; Ludlow, C.L.; Gaudet, R.; Houlden, H.; Reilly, M.M.; Fischbeck, K.H.; Sumner, C.J.; Timmerman, V.; Jordanova, A.; De Jonghe, P. Dominant mutations in the cation channel gene transient receptor potential vanilloid 4 cause an unusual spectrum of neuropathies. Brain, 2010, 133(6), 1798-1809.
168. Nilius, B.; Owsianik, G. Transient receptor potential channelopathies. Plfugers Arch., 2010, 460(2), 437-450.
169. Bruijn, L.I.; Miller, T.M.; Cleveland, D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci., 2004, 27, 723-749.
170. Rowland, L.P.; Shneider, N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med., 2001, 344(22), 1688-1700.
171. Mitchel, J.D. Amyotrophic lateral sclerosis: toxins and environment. Amyotroph. Lateral Scler. Other Motor Neuron Disord., 2000, 1(4), 235-250.
172. Hermosura, M.C.; Garruto, R.M. TRPM7 and TRPM2-Candidate Susceptibility Genes for Western Pacific ALS and PD? Biochim. Biophys. Acta, 2007, 1772(8), 822-835.
173. Garruto, R.M. A commentary on neuronal degeneration and cell death in Guam ALS and PD: an evolutionary process of understanding. Curr. Alzheimer Res., 2006, 3(4), 397-401.
174. Spencer, P.S.; Nunn, P.B.; Hugon, J.; Ludolph, A.C.; Ross, S.M.; Roy, D.N.; Robertson, R.C. Guam amyotrophic lateral sclerosisparkinsonism-dementia linked to a plant excitant neurotoxin. Science, 1987, 237(4814), 517-522.
175. Brownson, D.M.; Mabry, T.J.; Leslie, S.W. The cycad neurotoxic amino acid, beta-N-methylamino-L-alanine (BMAA), elevates intracellular calcium levels in dissociated rat brain cells. J. Ethnopharmacol., 2002, 82(2-3), 159-167.
176. Altura, B.M.; Gebrewold, A.; Zhang, A.; Altura, B.T. Low intracellular magnesium ions induce lipid peroxidation and activation of nuclear factor-kappa B in canine cerebral vascular smooth muscle: possible relation to traumatic brain injury and strokes. Neurosci. Lett., 2003, 341(3), 189-192.
177. Sayre, L.M.; Smith, M.A.; Perry, G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem., 2001, 8(7), 721-738.
178. Nadler, M.J.; Hermosura, M.C.; Inabe, K.; Perraud, A.L.; Zhu, Q.; Stokes, A.J.; Kurosaki, T.; Kinet, J.P.; Penner, R.; Scharenberg, A.M.; Fleig, A. LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell viability. Nature, 2001, 411(6837), 590-595.
179. Monteilh-Zoller, M.K.; Hermosura, M.C.; Nadler, M.J.; Scharenberg, A.M.; Penner, R.; Fleig, A. TRPM7 provides an ion channel mechanism for cellular entry of trace metal ions. J. Gen. Physiol., 2003, 121(1), 49-60.
180. Schmitz, C.; Perraud, A.L.; Johnson, C.O.; Inabe, K.; Smith, M.K.; Penner, R.; Kurosaki, T.; Fleig, A.; Scharenberg, A.M. Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7. Cell, 2003, 114(2), 191-200.
181. Hanano, T.; Hara, Y.; Shi, J.; Morita, H.; Umebayashi, C.; Mori, E.; Sumimoto, H.; Ito, Y.; Mori, Y.; Inoue, R. Involvement of TRPM7 in cell growth as a spontaneously activated Ca2+ entry pathway in human retinoblastoma cells. J. Pharmacol. Sci., 2004, 95(4), 403-419.
182. Krapivinsky, G.; Mochida, S.; Krapivinsky, L.; Cibulsky, S.M.; Clapham, D.E. The TRPM7 ion channel functions in cholinergic synaptic vesicles and affects transmitter release. Neuron, 2006, 52(3), 485-496.
183. Montell, C. Mg2+ homeostasis: the Mg2+nificent TRPM chanzymes. Curr. Biol., 2003, 13(20), R799-R801.
184. Hermosura, M.C.; Monteilh-Zoller, M.K.; Scharenberg, A.M.; Penner, R.; Fleig, A. Dissociation of the store-operated calcium current I (CRAC) and the Mg-nucleotide-regulated metal ion current MagNuM. J. Physiol., 2002, 539(2), 445-458.
185. Sano, Y.; Inamura, K.; Miyake, A.; Mochizuki, S.; Yokoi, H.; Matsushime, H.; Furuichi, K. Immunocyte Ca2+ influx system mediated by LTRPC2. Science, 2001, 293(5533), 1327-1330.
186. Perraud, A.L.; Knowles, H.M.; Schmitz, C. Novel aspects of signaling and ion-homeostasis regulation in immunocytes. The TRPM ion channels and their potential role in modulating the immune response. Mol. Immunol., 2004, 41(6-7), 657-673.
187. Kraft, R.; Grimm, C.; Grosse, K.; Hoffmann, A.; Sauerbruch, S.; Kettenmann, H.; Schultz, G.; Harteneck, C. Hydrogen peroxide and ADP-ribose induce TRPM2-mediated calcium influx and cation currents in microglia. Am. J. Physiol. Cell Physiol., 2004, 286(1), C129-C137.
188. Kuhn, F.J.; Luckhoff, A. Sites of the NUDT9-H domain critical for ADP-ribose activation of the cation channel TRPM2. J. Biol. Chem., 2004, 279(45), 46431-46437.
189. Heiner, I.; Eisfeld, J.; Warnstedt, M.; Radukina, N.; Jungling, E.; Luckhoff, A. Endogenous ADP-ribose enables calcium-regulated cation currents through TRPM2 channels in neutrophil granulocytes. Biochem. J., 2006, 398(2), 225-232.
190. Chinopoulos, C.; Adam-Vizi, V. Calcium, mitochondria and oxidative stress in neuronal pathology. Novel aspects of an enduring theme. FEBS J., 2006, 273(3), 433-450.
191. Cassarino, D.S.; Bennett, J.P., Jr. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res. Brain Res. Rev., 1999, 29(1), 1-25.
192. von Lewinski, F.; Keller, B.U. Ca2+, mitochondria and selective motoneuron vulnerability: implications for ALS. Trends Neurosci., 2005, 28(9), 494-500.
193. Mattson, M.P. Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Ann. NY Acad. Sci., 2004, 1012, 37-50.
194. Boillee, S.; Vande Velde, C.; Cleveland, D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron, 2006, 52(1), 39-59.
195. Boillee, S.; Yamanaka, K.; Lobsiger, C.S.; Copeland, N.G.; Jenkins, N.A.; Kassiotis, G.; Kollias, G.; Cleveland, D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science, 2006, 312(5778), 1389-1392.
196. Borchelt, D.R. Amyotrophic lateral sclerosis-are microglia killing motor neurons? N. Engl. J. Med., 2006, 355(15), 1611-1613.
197. Alexianu, M.E.; Kozovska, M.; Appel, S.H. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology, 2001, 57(7), 1282-1289.
198. Graves, M.C.; Fiala, M.; Dinglasan, L.A.; Liu, N.Q.; Sayre, J.; Chiappelli, F.; van Kooten, C.; Vinters, H.V. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph. Lateral Scler. Other Motor Neuron Disord., 2004, 5(4), 213-219.
199. Murch, S.J.; Cox, P.A.; Banack, S.A. A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proc. Natl. Acad. Sci. USA, 2004, 101(33), 12228-12231.
200. Chan, C.S.; Gertler, T.S.; Surmeier, D.J. Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci., 2009, 32(5), 249-256.
201. Surmeier, D.J. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol., 2007, 6(10), 933-938.
202. Dorsey, E.R.; Constantinescu, R.; Thompson, J.P.; Biglan, K.M.; Holloway, R.G.; Kieburtz, K.; Marshall, F.J.; Ravina, B.M.; Schifitto, G.; Siderowf, A.; Tanner, C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 2007, 68(5), 384-386.
203. Chinopoulos, C.; Starkov, A.A.; Fiskum, G. Cyclosporin Ainsensitive permeability transition in brain mitochondria: inhibition by 2-aminoethoxydiphenyl borate. J. Biol. Chem., 2003, 278(30), 27382-27389.
204. Venkatachalam, K.; van Rossum, D.B.; Patterson, R.L.; Ma, H.T.; Gill, D.L. The cellular and molecular basis of store-operated calcium entry. Nat. Cell Biol., 2002, 4(11), E263-E272.
205. Imai, Y.; Soda, M.; Inoue, H.; Hattori, N.; Mizuno, Y.; Takahashi, R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell, 2001, 105(7), 891-902.
206. Yang, Y.; Nishimura, I.; Imai, Y.; Takahashi, R.; Lu, B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron, 2003, 37(6), 911-924.
207. Murakami, T.; Shoji, M.; Imai, Y.; Inoue, H.; Kawarabayashi, T.; Matsubara, E.; Harigaya, Y.; Sasaki, A.; Takahashi, R.; Abe, K. Pael-R is accumulated in Lewy bodies of Parkinson's disease. Ann. Neurol., 2004, 55(3), 439-442.
208. Rezgaoui, M.; Süsens, U.; Ignatov, A.; Gelderblom, M.; Glassmeier, G.; Franke, I.; Urny, J.; Imai, Y.; Takahashi, R.; Schaller, H.C. The neuropeptide head activator is a high-affinity ligand for the orphan G-protein-coupled receptor GPR37. J. Cell Sci., 2006, 119(Pt 3), 542-549.
209. Starowicz, K.; Maione, S.; Cristino, L.; Palazzo, E.; Marabese, I.; Rossi, F.; de Novellis, V.; Di Marzo, V. Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J. Neurosci., 2007, 27(50), 13739-13749.
210. de Lago, E.; de Miguel, R.; Lastres-Becker, I.; Ramos, J.A.; Fernandez-Ruiz, J. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Res., 2004, 1007, 152-159.
211. Lastres-Becker, I.; Molina-Holgado, F.; Ramos, J.A.; Mechoulam, R.; Fernández-Ruiz, J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis., 2005, 19(1-2), 96-107.
212. García-Arencibia, M.; González, S.; de Lago, E.; Ramos, J.A.; Mechoulam, R.; Fernández-Ruiz, J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptorindependent properties. Brain Res., 2007, 1134(1), 162-1670.
213. Meissner, W.; Prunier, C.; Guilloteau, D.; Chalon, S.; Gross, C. E.; Bezard, E. Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. Mol. Neurobiol., 2003, 28, 209-218.
214. Schindowski, K.; Belarbi, K.; Buee, L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav., 2008, 7(1), 43-56.
215. Bertram, L.; Tanzi, R.E. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat. Rev. Neurosci., 2008, 9(10), 768-778.
216. Khachaturian, Z.S. Calcium, membranes, aging, and Alzheimer's disease. Introduction and overview. Ann. NY Acad. Sci., 1989, 568, 1-4.
217. Kuchibhotla, K.V.; Goldman, S.T.; Lattarulo, C.R.; Wu, H.Y.; Hyman, B.T.; Bacskai, B.J. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron, 2008, 59(2), 214-225.
218. Tu, H.; Nelson, O.; Bezprozvanny, A.; Wang, Z.; Lee, S.F.; Hao, Y.H.; De Strooper, B.; Yu, G.; Bezprozvanny, I. Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell, 2006, 126(5), 981-993.
219. Itkin, A.; Dupres, V.; Dufrêne, Y.F.; Bechinger, B.; Ruysschaert, J.M.; Raussens, V. Calcium ions promote formation of amyloid β-peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease. PLoS One, 2011, 6(3), e18250.
220. Mattson, M.P.; Barger S.W.; Cheng, B.; Lieberburg, I.; Smith-Swintosky, V.L.; Rydel, R.E. beta-Amyloid precurson protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease. Trends Neurosci., 1993, 16(10), 409-414.
221. Mattson, M.P.; Engle, M.G.; Rychlik, B. Effects of elevated intracellular calcium levels on the cytoskeleton and tau in cultured human cortical neurons. Mol. Chem. Neuropathol., 1991, 15(2), 117-142.
222. Mattson, M.P.; LaFerla, F.M.; Chan, S.L.; Leissring, M.A.; Shepel, P.N.; Geiger, D. Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci., 2000, 23(5), 222-229.
223. Aarts, M.M.; Tymianski, M. TRPM7 and ischemic CNS injury. Neuroscientist, 2005, 11(2), 116-123.
224. Park, M.H.; Choi, D.Y.; Jin, H.W.; Yoo, H.S.; Han, J.Y.; Oh, K.W.; Han, S.B.; Hwang, D.Y.; Hong, J.T. Mutant presenilin 2 increases β-secretase activity through reactive oxygen speciesdependent activation of extracellular signal-regulated kinase. J. Neuropathol. Exp. Neurol., 2012, 71(2), 130-139.
225. Li, H.S.; Xu, X.Z.; Montell, C. Activation of a TRPC3-dependent cation current through the neurotrophin BDNF. Neuron, 1999, 24(1), 261-273.
226. Elliott, E.; Ginzburg, I; The role of neurotrophins and insulin on tau pathology in Alzheimer's disease. Rev. Neurosci., 2006, 17(6), 635-642.
227. Chen, Q.; Zhou, Z.; Zhang, L.; Wang, Y.; Zhang, Y.; Zhong, M.; Xu, S.; Chen, C.; Li, L.; Yu, Z. Tau protein is involved in morphological pasticity in hippocampal neurons in response to BDNF. Neurochem. Int., 2012, 60(3), 233-242.
228. Micale, V.; Cristino, L.; Tamburella, A.; Petrosino, S.; Leggio, G.M.; Drago, F.; Di Marzo, V. Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems. Neurobiol. Dis., 2009, 36(1), 70-80.
229. Abdul, H.M.; Sultana, R.; Keller J.N.; St. Clair, D.K.; Markesbery, W.R.; Butterfield, D.A. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to insreased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainc acid: implication in Alzheimer's disease. J. Neurochem., 2006, 96(5), 1322-1335.
230. Walker, D.G.; Kim, S.U.; McGeer, P.L. Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. J. Neurosci. Res., 1995, 40(4), 478-493.
231. Lee, M.; Cho, T.; Jantaratnotai, N.; Wang Y.T.; McGeer, E.; McGeer PL. Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB J., 2010, 24(7), 2533-2545.
232. Mathie, A.; Sutton, G.L.; Clarke, C.E.; Veale, E.L. Zinc and copper: pharmacological probes and endogenous modulators of neuronal excitability. Pharmacol. Ther., 2006, 111(3), 567-583.
233. Smith J.L.; Xiong, S.; Markesbery, W.R.; Lovell, M.A. Altered expression of zinc transporters-4 and-6 in mild cognitive impairment, early and late Alzheimer's disease brain. Neuroscience, 2006, 140(3), 879-888.